CAR-T vs Stem Cell Transplant — Which and When?

They do different jobs. CAR-T reprograms your own T cells in a laboratory and returns them as one infusion, so they can recognise a marker on the cancer cells. A stem cell transplant replaces the blood-forming stem cells in your marrow — with your own cells, or with a donor’s. Only one of them needs a donor.

First, an important split in the word “transplant”. People search for “bone marrow transplant” as if it were one operation. It is two very different treatments. An autologous transplant gives you back your own stem cells, collected earlier and frozen, purely to rescue your marrow after very high-dose chemotherapy. An allogeneic transplant gives you a donor’s stem cells, which rebuild your blood and bring a new immune system with them. The donor immune system is doing part of the work against the cancer — and is also the reason graft-versus-host disease exists. Almost every confusing conversation about “CAR-T versus transplant” is really a conversation about which of these two you were offered.

Said plainly, before anything else: CION Cancer Clinics does not provide CAR-T cell therapy or any other cell therapy, and does not perform stem cell transplantation. We do not administer, stock or manufacture any of it, and we quote no price for any of it. This page exists so you can understand the fork you are standing at, and so we can point you to an accredited centre when one of these pathways is genuinely on the table for your diagnosis.

There is no universal order. The sequence is set by the diagnosis and subtype, how long the first remission lasted, whether the disease still responds to chemotherapy, your fitness, and whether a donor exists. In some relapsed lymphomas guideline bodies now place CAR-T ahead of transplant. In several leukaemias, donor transplant stays first.

This is a genuine decision fork, not a ranking. It is decided by a haemato-oncologist who has your marrow report, your immunophenotyping, your imaging and your full treatment history in front of them. What follows is the framework they work through — so you can follow the conversation and ask the right question at the right moment.

The six questions that set the order

1. What exactly is the diagnosis? Approved CAR-T use sits almost entirely in relapsed or refractory B-cell acute lymphoblastic leukaemia, several B-cell lymphomas, and multiple myeloma after several prior lines. Transplant is used across a far wider set of blood cancers and some marrow failure states. In many diagnoses only one of the two is on the table at all.
2. Does the disease still respond to chemotherapy? An autologous transplant depends on the disease being chemotherapy-sensitive, because the high-dose conditioning is what is meant to act on it. Disease that has not responded to salvage chemotherapy is the classic situation in which that pathway is set aside.
3. How long did the first remission last? Early relapse and primary refractory disease behave differently from a relapse years later, and guideline bodies including NCCN and ESMO treat them differently. For some large B-cell lymphomas that relapse within a year, CD19-directed CAR-T has moved ahead of autologous transplant in the recommended sequence.
4. Is there a donor, and how long will finding one take? A matched sibling can be typed in days. A matched unrelated or half-matched donor takes longer to arrange and costs more. If no donor is realistically available in the time your disease allows, that answers part of the question for you.
5. Are you fit enough for conditioning? Age, organ function, performance status, infection and previous treatment all count. Reduced-intensity conditioning widened who can have an allogeneic transplant, but it did not remove the requirement to be well enough to get through it.
6. Is a clinical trial open and appropriate? In relapsed blood cancers a trial is a legitimate option to ask about, not a last resort. Ask whether one is open at the centre, what it involves, and what happens if you are not eligible. A trial place is never certain.

The option nobody puts on the list. Not proceeding to either pathway is a real option, and for some people it is the right one. If the disease, the fitness or the timing means neither treatment is likely to help, a plan built around symptom control and quality of life is a legitimate medical decision, not a failure to try. Ask your team directly what they would advise if you were their family, and ask them to say plainly what each pathway is intended to achieve in your case.

Yes — in sequence, in selected situations, and never at the same time. Both directions happen. CAR-T is used after a transplant has failed. An allogeneic transplant is used after CAR-T in some patients as consolidation. Which direction applies to you depends on the diagnosis and on how the disease behaves.

• CAR-T after a transplant. Relapse after an autologous or allogeneic transplant does not automatically rule CAR-T out. It is one of the situations the treatment was developed for. The centre will assess how much healthy T-cell material can still be collected.
• A transplant after CAR-T. Some patients, particularly younger patients with B-cell acute lymphoblastic leukaemia, go on to an allogeneic transplant after CAR-T as consolidation. Whether that is advised depends on the response, on how long the modified cells persist, and on donor availability.
• Not at the same time, and not as a backup plan you can switch to freely. Each pathway takes weeks of preparation and has its own eligibility assessment. Relapsed disease can progress while either is being arranged, which is why centres run bridging treatment.
• Order affects what stays possible. Heavy chemotherapy before collection can reduce T-cell quality for CAR-T manufacture. Say early, in writing, if CAR-T may be part of the plan at any stage, so that the collection question is settled before the next line begins.
• Both remain referral pathways. Neither is delivered at CION. Both are delivered only at units licensed for them, and the licensing exists because of what can go wrong in the first weeks.

Both start with referral to a licensed unit and an eligibility assessment. CAR-T then adds a manufacturing wait of roughly two to six weeks. A donor transplant instead adds a donor search, which can take weeks to months. The monitoring afterwards is where the two diverge most.

Two practical consequences follow from that table. First, both pathways mean living near the treating centre for weeks, which for most families in Telangana and Andhra Pradesh means another city and a second set of costs. Our page on travelling to another city for CAR-T covers that planning in detail, and most of it applies equally to a transplant. Second, neither pathway is a single appointment you can slot into a working month. Plan for the whole block of time, not the infusion date.

Transplant is the more available and the less expensive of the two. Transplant units operate in most large Indian cities. CAR-T is delivered at a small number of accredited centres. All figures below are indicative, as of August 2026, drawn from published announcements and reported news — not from a CION rate card.

Read these as planning ranges, not quotations. What a family is finally charged depends on the centre, the diagnosis, how much bridging treatment is needed and whether a complication occurs. Ask for a written estimate itemised into product or donor costs, hospital stay, and monitoring, and ask specifically what is excluded. Aarogyasri and other scheme ceilings, where they apply, are set by the scheme and not by the hospital — ask the centre’s counsellor to show you the current ceiling in writing before you commit.

Five questions, asked at the first consultation, settle most of the confusion. Write the answers down. If the answer to any of them is vague, that is itself information about the pathway you are being offered.

• Which pathway are you actually recommending for my diagnosis, and why that one first? Ask for the reasoning, not just the name of the treatment.
• If we choose this one, what does it close off later? This is the sequencing question, and it is the one families most often ask too late.
• What is your unit’s current timeline, from today to the infusion or transplant date? Ask for it in weeks, and ask what would make it longer.
• What is the written, itemised estimate, and what is excluded from it? Product or donor costs, hospital stay, complication treatment and the first year afterwards should all be visible separately.
• What happens if I am found ineligible, or the batch or donor falls through? Ask for the fallback plan before you need it, including whether a trial is open.

If you want a second pair of eyes on the answers, that is exactly what a second opinion is for. Bring the estimate and the plan, not just the diagnosis.

No. CION Cancer Clinics does not administer, stock or manufacture CAR-T or any other cell therapy, and does not perform stem cell transplantation. Both are referral pathways to units licensed for them. This page is orientation and referral guidance, and nothing on it is an offer of either treatment.

What CION does do. A medical oncologist will read your reports free of charge and tell you plainly whether CAR-T or a transplant is genuinely in the conversation for your diagnosis, what each would involve in time and money, and what the realistic alternatives are. Where referral to an accredited cell-therapy or transplant unit is the right next step, we will say so and help you get there with a complete record. Where it is not, we will say that too.

The immunotherapy CION does provide is checkpoint-inhibitor treatment, given as day care at CION centres. It is a different class of treatment from cell therapy, and it is not a substitute for it. Response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION. You can read more on the immunotherapy at CION Cancer Clinics hub.

• Apheresis: Collecting Your Cells for CAR-T — the collection step that has no equivalent in an allogeneic transplant, and the one that prior chemotherapy can compromise.
• Bridging Therapy: Treatment While You Wait for CAR-T — what happens during the manufacturing wait, and why the same idea is used while a transplant date is arranged.
• Travelling to Another City for CAR-T: Practical Planning — weeks near the centre, accommodation and the costs a package quote leaves out; most of it applies to a transplant too.
• Immunotherapy at CION Cancer Clinics — the treatments CION does provide, how eligibility is assessed, and what a free first consultation actually covers.

Most families reach this page holding two enormous options and one deadline

Ask us what your diagnosis actually calls for. You will get a plain answer, including when the answer is that neither pathway is relevant to your case.